Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects aged 6-12 years, inclusive.~* Subjects meeting the DSM-IV criteria for primary diagnosis of ADHD-Combined type, or predominantly hyperactive-impulsive subtype, as established by the K-SADS-PL (Kiddie Schedule for Affective Disorders and Schizophrenia-Present and Lifetime Version). If a DSM-IV-defined ADHD diagnosis is difficult to establish due to possible co-morbidity, the subject will not be enrolled into the study.~* Subjects should be on a stabilized total daily dose or nearest equivalent of 40-60 mg methylphenidate or 20-30 mg of d-methylphenidate for at least two weeks prior to Screening visit.~Exclusion Criteria:~* Subject or subject's guardian unable to understand or follow instructions necessary to participate in the study.~* Diagnosed with or history of a tic disorder or Tourette's syndrome.~* History of seizure disorder.~* The presence of a known medical condition that would preclude the use of methylphenidate.~* A history (within the past year) or presence of clinically significant cardiovascular, cerebrovascular, renal, hepatic, gastrointestinal, pulmonary, immunological, hematological, endocrine, or neurological disease.~* ALT (Alanine Amino Transferase), AST (Aspartate Amino Transferase), GGT (Gamma glutamyl transferase) or serum creatinine greater then 2X the ULN (Upper Limit of Normal) at Screening.~* A history of psychiatric illness or substance use disorder (e.g., schizophrenia, bipolar disorder, autism, abuse or dependence, depression, severe Conduct Disorder or severe Oppositional defiant disorder)~* Subjects who have participated in an investigational trial within the past 4 weeks (28 days)~* Subjects who are currently taking antidepressants or other psychotropic medication.~* Subjects who have initiated psychotherapy during the three months prior to randomization.~* Subjects with a positive urine drug screen.~* Subjects who have a history of poor response or intolerance to methylphenidate or d-methylphenidate.~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Dex-Methylphenidate hydrochloride (Focalin® XR) 30 mg (Type: EXPERIMENTAL): Dex-Methylphenidate hydrochloride (Focalin® XR) 30 mg dose (one 20 mg capsule and one 10 mg capsule) orally once a day for 7 days.
- Dex-Methylphenidate hydrochloride (Focalin® XR) 20 mg (Type: ACTIVE_COMPARATOR): Dex-Methylphenidate hydrochloride (Focalin® XR) one 20 mg capsule orally once a day for 7 days.
- Placebo (Type: PLACEBO_COMPARATOR): Two Capsules taken orally once a day for 7 days

Based on this trial design, predict the completion outcome and termination type (if applicable).